SCHEMBL21286640

SCHEMBL21286640

CC(C)c1cc(Cc2c(Cl)cc(OCC(=O)NC[C@@H](C)O)cc2Cl)ccc1O

nearest known ligand 0.72

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
THRB P10828 20/20 0.72
THRA P10827 19/20 0.72

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21286641 1.00 THRB (0.72) THRBTHRA
SCHEMBL21286691 1.00 THRB (0.72) THRBTHRA
SCHEMBL21286684 0.93 THRB (0.63) THRBTHRA
SCHEMBL24632178 0.93 THRB (0.73) THRBTHRA
SCHEMBL21286586 0.91 THRB (0.70) THRBTHRA
SCHEMBL21286550 0.90 THRB (0.74) THRBTHRA
SCHEMBL24632225 0.89 THRB (0.71) THRBTHRA
SCHEMBL19859393 0.89 THRB (0.71) THRBTHRA
SCHEMBL24632226 0.89 THRB (0.71) THRBTHRA
Abx-002 SCHEMBL19634315 0.88 THRB (0.79) THRBTHRA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11578032-B2 Derivatives of sobetirome OREGON HEALTH & SCIENCE UNIVERSITY (US) 2023-02-14 US disclosed
WO-2022236133-A1 FATTY ACID AMIDE HYDROLASE (FAAH) CLEAVABLE PRODRUGS OF THYROMIMETICS AND COMBINATION WITH PERIPHERALLY RESTRICTED FAAH INHIBITORS AUTOBAHN THERAPEUTICS, INC. (US) 2022-11-10 WO disclosed
US-20210002208-A1 DERIVATIVES OF SOBETIROME OREGON HEALTH & SCIENCE UNIVERSITY (US) 2021-01-07 US disclosed
WO-2019160980-A1 DERIVATIVES OF SOBETIROME OREGON HEALTH & SCIENCE UNIVERSITY (US) 2019-08-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210002208-A1 DERIVATIVES OF SOBETIROME SLC6A3, TPH1, SLC6A2 THRB 149/4885THRA 213/4885
US-11578032-B2 Derivatives of sobetirome SLC6A3, TPH1, SLC6A2 THRB 149/4885THRA 213/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.